Notícias

BioVersys Reports Results From Phase 2a ENABLE Study

NASDAQ

(RTTNews) - BioVersys AG (BIOV.SW) announced results from the Phase 2a ENABLE study of alpibectir in combination with ethionamide or AlpE in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. The phase 2a ENABLE study showed early bactericidal activity in all re

Ler o briefing completo da Veytics

Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.